Drug Trial Radar · NCT06412666
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
65
Planned (sponsor's estimate)
Start
May 29, 2024
Primary completion
Jan 2030
Study completion Jan 2030
Sponsor
- Lead sponsor
- CytokineticsIndustry
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- May 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Conditions
- Pediatric
- Symptomatic Obstructive Hypertrophic Cardiomyopathy
Interventions
AficamtenDrug
Oral Tablet
PlaceboDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Valsalva left ventricular outflow tract gradient (LVOT-G)Time frame: Baseline to week 12 (Period 1)
Locations
36 sites in 6 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
Children's Hospital Los Angeles
Los Angeles, California
University of California, Los Angeles (UCLA)
Los Angeles, California
Children's Hospital Colorado
Aurora, Colorado
Children's National Hospital
Washington D.C., District of Columbia
Nicklaus Children's Hospital
Miami, Florida
Ann & Robert H. Lurie Children's Hospital
Chicago, Illinois
University of Michigan
Ann Arbor, Michigan
Children's Hospital of Michigan
Detroit, Michigan
Mayo Clinic
Rochester, Minnesota
Children's Mercy Hospital
Kansas City, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Morristown Medical Center
Morristown, New Jersey
NYP/Columbia University Medical Center
New York, New York
Children's Hospital at Montefiore
The Bronx, New York
Duke Clinical Research Institute
Durham, North Carolina
Oregon Health & Science University
Portland, Oregon
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
LeBonheur Children's Hospital
Memphis, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Dell Children's Hospital
Austin, Texas
UT Southwestern
Dallas, Texas
Children's Wisconsin
Milwaukee, Wisconsin
The Hospital for Sick Children (SickKids)
Toronto, Ontario, Canada
Azienda Ospedaliera Universitaria Meyer IRCCS
Florence, Italy
NHO Kagoshima Medical Center
Kagoshima, Japan
University of Osaka Hospital
Osaka, Japan
Kitasato University Hospital
Sagamihara, Japan
National Cerebral and Cardiovascular Center
Suita, Japan
Juntendo University Hospital
Tokyo, Japan
Unidad de Cardiología Infantil; Hospital Universitario da Coruña
A Coruña, Spain
Hospital Sant Joan de Deu
Barcelona, Spain
Alder Hey Children's Hospital
Liverpool, United Kingdom
Evelina Children's Hospital
London, United Kingdom
Great Ormond Street Hospital for Children
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.